<DOC>
	<DOCNO>NCT00783224</DOCNO>
	<brief_summary>This study conduct see mometasone nasal spray efficaceous treatment perennial allergic rhinitis . Patients randomize active mometasone , placebo mometasone , active fluticasone , placebo fluticasone .</brief_summary>
	<brief_title>A Comparative Study Mometasone Furoate Nasal Spray Fluticasone Propionate Nasal Spray Patients With Perennial Allergic Rhinitis ( Study P04512 )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Perennial</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Patients perennial allergic rhinitis meeting following . Patients symptoms perennial allergic rhinitis , severity moderate severer accord severity grading provide `` Guidelines Management Allergic Rhinitis Japan '' ( partly modify ) 4nasal symptom score 4 informed consent pretreatment observation period Patients positive reaction eosinophil count nasal discharge nasal challenge test addition skin test specific IgE antibody test Outpatients age 16 year informed consent Patients either sex Patients ( legal representative case patient age 20 year ) capable give write informed consent Patients capable record nasal allergy diary every day Patients complication tuberculous disease low respiratory tract infection , complication otorhinolaryngeal infection ( acute upper respiratory tract inflammation , acute laryngopharyngitis , acute tonsillitis , etc . ) require treatment judge investigator ( subinvestigator ) time enrollment randomization Patients complication infection systemic mycosis effective antibiotic available Patients complication recurrent epistaxis Patients uncured nasal septal ulcer , operate nose nasal trauma . Patients history hypersensitivity steroids ingredient study drug Pregnant , lactate possibly pregnant patient patient whose partner wish become pregnant study Patients severe hepatic renal disorder , heart blood disease , diabetes mellitus , hypertension , serious complication , suffer problem systemic condition Patients pollens multiple allergen period 7 day enrollment randomization completion treatment period coincides period scatter relevant pollen Patients complication vasomotor rhinitis eosinophilic rhinitis Patients complication nasal disease ( infectious sinusitis , hypertrophic rhinitis , acute chronic rhinitis , nasal polyp , septal deviation ) may interfere efficacy evaluation study drug Patients complication disease ( acute upper respiratory tract inflammation , acute laryngitis acute tonsillitis , etc . ) severity affect nasal symptom within 7 day enrollment Patients previously receive MF nasal spray Patients use FP nasal spray within 28 day initiation pretreatment observation period ( 7 day enrollment randomization ) Patients participate clinical trial investigational product ( ) within 120 day ( 4 month ) obtain informed consent participate present Patients prior medication expect effective allergic rhinitis drawn long enough initiation treatment investigational product precede medication withdrawn Patients treat specific desensitization therapy nonspecific allassotherapy therapy withdrawn within 90 day ( 3 month ) obtain inform consent ( except patient receive maintenance therapy present therapy begin 180 day ( 6 month ) obtain informed consent ) Other patient investigator subinvestigator judge inappropriate participation present study</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>